Skip to main content
. 2020 Jul 10;8:703. doi: 10.3389/fbioe.2020.00703

FIGURE 4.

FIGURE 4

Cost of monovalent recombinant antivenoms against four representative species of venomous snakes. The calculations were conducted for three different toxin-to-antibody ratios (i.e., 2:1, 1:1, and 1:3) and assumed that either 25% (yellow), 50% (orange), or 100% (red) of the maximum venom yield needs to be neutralized. The calculations are for Cost of Goods Manufactured for the Final Drug Product for a full treatment of a given snakebite (COGMFDP) and, thus, include formulation and packaging costs.